Results 31 to 40 of about 37,241 (266)

Molecular mechanism of antihistamines recognition and regulation of the histamine H1 receptor

open access: yesNature Communications
Histamine receptors are a group of G protein-coupled receptors (GPCRs) that play important roles in various physiological and pathophysiological conditions.
Dandan Wang   +7 more
doaj   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu   +9 more
wiley   +1 more source

Systematic review about 10 interventions in dermatitis. A document from the Latin American Society of Allergy, Asthma, and Immunology

open access: yesRevista Alergia México, 2019
The Latin American Society of Allergy, Asthma, and Immunology (SLAAI) conducted a systematic search in the Medline and LILACS’ database in order to get articles linked to 10 current questions about dermatitis.
Jorge Sánchez   +11 more
doaj   +1 more source

Anomeric Amide Enabled Divergent Synthesis of Unsymmetrical Ureas, Carbamates, Thioesters, and Amides From Aldehydes

open access: yesAngewandte Chemie International Edition, EarlyView.
An anomeric amide‐enabled divergent aldehyde functionalization sequence provides one‐pot access to unsymmetrical ureas, carbamates, thiocarbamates, thioesters, and amides. Key to this transformation is the formation of N‐Boc‐hydroxamate intermediates, which serve as platforms for orthogonal activation via Lossen‐type rearrangements, single‐electron ...
Jasper L. Tyler   +6 more
wiley   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

open access: yesArthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf   +15 more
wiley   +1 more source

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm

open access: yesFrontiers in Allergy, 2021
Allergic rhinitis in childhood has been often missed, mistreated and misunderstood. It has significant comorbidities, adverse effects upon quality of life and educational performance and can progress to asthma or worsen control of existing asthma ...
Glenis Kathleen Scadding   +18 more
doaj   +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort   +3 more
wiley   +1 more source

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura   +6 more
wiley   +1 more source

Use of second-generation antihistamines in combination treatment of ENT diseases

open access: yesМедицинский совет, 2015
Currently, allergic diseases are very widespread, and their incidence is increasing at an alarming pace worldwide. [1] According to different authors, from 20 to 50% of the population in European countries suffer from allergic diseases.
A. I. Kryukov   +5 more
doaj   +1 more source

Primary Non-Adherence to Antihistamines—Conclusions From E-Prescription Pilot Data in Poland

open access: yesFrontiers in Pharmacology, 2020
BackgroundIn allergic conditions such as allergic rhinitis and urticaria, orally administered H1-antihistamines belong to first-line therapy and therefore, are widely prescribed.
Grzegorz Kardas   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy